Ian F. Smith

Ian F. Smith

Chief Executive OfficeratStoke Therapeutics· In proxies 2023–2025

Pay in FY2025Stoke Therapeutics stock +187.8% the same year

Ian F. Smith was paid $27.0M in FY2025 (Dec). Stoke Therapeutics stock rose 187.8% that year.

Pay$100 in the stock at the end of FY24 → $288
Pay is from the Summary Compensation Table of each Stoke Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Stoke TherapeuticsPublic company · 3 yr
    • Chief Executive Officer2023 – Present · 3 yrStock in role +222%
  2. Areteia TherapeuticsPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  3. Odyssey TherapeuticsPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  4. Directors for Rivus PharmaceuticalPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  5. Alkeus PharmaceuticalsPublic company · 4 yr
    • Director2022 – Present · 4 yrNo stock prices for these years
  6. Alkeus TherapeuticsPublic company · 4 yr
    • Director2022 – Present · 4 yrNo stock prices for these years
  7. Foghorn TherapeuticsPublic company · 5 yr
    • Director2021 – Present · 5 yrNo stock prices for these years
  8. Solid BiosciencesPublic company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years
  9. ViacytePublic company · 3 yr
    • Director2019 – 2022 · 3 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?